VIP: The big shot peptide in pregnancy and beyond?
Open Access
- 25 February 2021
- journal article
- editorial
- Published by Wiley in Acta Physiologica
- Vol. 232 (1), e13636
- https://doi.org/10.1111/apha.13636
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Development of the human placentaDevelopment, 2019
- Placental bed research: II. Functional and immunological investigations of the placental bedAmerican Journal of Obstetrics and Gynecology, 2019
- Vasoactive Intestinal Peptide Ameliorates Acute Myocarditis and Atherosclerosis by Regulating Inflammatory and Autoimmune ResponsesJournal Of Immunology, 2018
- Control of the inflammatory response during pregnancy: potential role of VIP as a regulatory peptideAnnals of the New York Academy of Sciences, 2018
- NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary DiseasePLOS ONE, 2017
- Placental Origins of Chronic DiseasePhysiological Reviews, 2016
- VIP modulates the pro‐inflammatory maternal response, inducing tolerance to trophoblast cellsBritish Journal of Pharmacology, 2008
- Effects of vasoactive polypeptides on the uterine vasculatureAmerican Journal of Obstetrics and Gynecology, 1981
- Vasoactive intestinal polypeptide (VIP) inhibits prostaglandin-F2α-induced activity of the rabbit myometriumProstaglandins, 1980
- Vasoactive intestinal polypeptide (VIP) inhibits oxytocin induced activity of the rabbit myometriumActa Physiologica Scandinavica, 1979